Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female 9 years of age or older~2. Females must not be pregnant or planning to get pregnant and must use acceptable form of contraception~3. Must be able to self-administer study medication~4. Must be able to understand and sign an informed consent form. For minor subjects, the subject's parent or legal guardian must provide permission by signing an ICF on behalf of the subject and the subject should provide assent.~Exclusion Criteria:~1. Congenital ptosis~2. Horner syndrome~3. Myasthenia gravis~4. Mechanical ptosis~5. Previous ptosis surgery~6. Resting heart rate outside the normal range~7. Hypertension with resting diastolic blood pressure~8. Pregnancy or lactation

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RVL-1201 ophthalmic solution 0.1% (Type: EXPERIMENTAL): RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
- Vehicle ophthalmic solution (Type: PLACEBO_COMPARATOR): Vehicle placebo ophthalmic solution

Based on this trial design, predict the completion outcome and termination type (if applicable).